Although the recent development of cancer immunotherapy raises high hope for cancer treatment, a major limitation of the current immune checkpoint blockade is the low response rate. Our observations suggest that the Hippo pathway is a new target for cancer immunotherapy since improving immunogenicity of cancer cells by inhibiting Hippo pathway is a strategy complementary to the current immunotherapy of relieving immune suppression. We aim to provide scientific bases to target the Hippo intracellular pathway for cancer immunotherapy.